Tiny study aims to sharpen MRI scans by tweaking dye injection
NCT ID NCT07346131
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests how the speed and volume of a contrast agent injection affect MRI image quality. Ten healthy volunteers will each have five abdominal MRI scans with different injection methods. Three radiologists will then rate the images to find the best approach, which could help improve future scans.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- gadopiclenol (a gadolinium-based contrast agent)
- What this could lead to
- If successful, this could help doctors choose the best injection method for clearer MRI images, potentially improving diagnosis.
- What could go wrong
- This is a very small, early-phase study in healthy volunteers, not patients. Results may not apply to real-world medical imaging or different populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
14 people
The number who actually took part.
- Started
-
Jan 2026
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults ≥18 and ≤ 40 years of age at time of Informed Consent * Informed Consent as documented by signature * No known chronic conditions (defined by ICD-10 codes) * Non-smoking * French speaking Exclusion Criteria: * Women who are pregnant or breast feeding, * Intention to become pregnant during the course of the study, * Contraindications to the class of drug (gadopiclenol and gadoteric acid) under study, e.g. known hypersensitivity or allergy * Claustrophobia and contraindication for MRI according to institutional practices * Prior MRI examination with contrast agent and washout period of ≤ 2 weeks * Prior liver, spleen, pancreatic or bowel surgery * Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) * Known or suspected non-compliance, drug or alcohol abuse * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Participation in another study with investigational medicinal product within the 30 days preceding and during the present study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Contrast agent are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HFR Hôpital fribourgeois
Fribourg, Canton of Fribourg, 1700, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.